Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 1,000 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel bought 1,000 shares of the stock in a transaction dated Friday, March 10th. The stock was bought at an average cost of $12.12 per share, with a total value of $12,120.00. Following the purchase, the chief executive officer now owns 2,737,486 shares in the company, valued at approximately $33,178,330.32. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Snehal Patel also recently made the following trade(s):

• On Friday, February 17th, Snehal Patel purchased 600 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $16.53 per share, with a total value of $9,918.00.
• On Friday, February 10th, Snehal Patel purchased 1,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $18.68 per share, with a total value of $18,680.00.
• On Friday, January 27th, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $19.35 per share, for a total transaction of $38,700.00.
• On Friday, January 20th, Snehal Patel bought 1,500 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $17.37 per share, for a total transaction of $26,055.00.
• On Friday, January 6th, Snehal Patel bought 1,500 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $15.18 per share, for a total transaction of $22,770.00.
• On Friday, December 16th, Snehal Patel bought 1,000 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $13.01 per share, for a total transaction of $13,010.00.

Greenwich LifeSciences Stock Up 8.0 %

Greenwich LifeSciences stock opened at $13.09 on Tuesday. The company has a market capitalization of $167.81 million, a P/E ratio of -22.96 and a beta of 0.99. The stock’s 50 day moving average is $16.62 and its 200 day moving average is $12.94. Greenwich LifeSciences, Inc. has a twelve month low of $6.82 and a twelve month high of $24.46.

Institutional Trading of Greenwich LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in GLSI. Vanguard Group Inc. grew its stake in shares of Greenwich LifeSciences by 150.2% in the 1st quarter. Vanguard Group Inc. now owns 375,200 shares of the company’s stock worth $7,362,000 after buying an additional 225,213 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $891,000. Millennium Management LLC purchased a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $765,000. Occudo Quantitative Strategies LP purchased a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $199,000. Finally, Pura Vida Investments LLC purchased a new stake in shares of Greenwich LifeSciences in the 3rd quarter worth approximately $179,000. Hedge funds and other institutional investors own 6.18% of the company’s stock.

Greenwich LifeSciences Company Profile

(Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.